24
Jun-2020
Jun-2020
Hamilton’s Fusion Pharmaceuticals Inc. has increased its planned initial public offering on the Nasdaq by half and now hopes to raise up to US$230-million, the biotechnology developer said late Wednesday. The cancer drug developer filed Monday to go public, laying out plans to sell 8.35 million shares at US$14 to US$16 apiece, plus an option […]
0 comments / 0 votes
Century Therapeutics today announced its acquisition of Empirica Therapeutics to leverage its iPSC-derived allogeneic cell therapies against glioblastoma (GBM). “We are pleased to welcome the Empirica team to the Century family. Their deep expertise and unique capabilities will allow us to accelerate efforts to develop iPSC derived immune effector cell products designed to treat and […]
0 comments / 0 votes